Epilepsy, Dravet Syndrome
Conditions
Keywords
Cannabidiol, CBD, Epidiolex, GWP42003-P
Brief summary
To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.
Detailed description
GWEP1332 Part B recruited an entirely new group of participants than GWEP1332 Part A. Participants who failed the entry criteria for Part A were eligible to take part in Part B. Part B was a 1:1 randomized, double-blind, placebo-controlled, 14-week comparison of GWP42003-P versus placebo. The aim of Part B was to assess the antiepileptic efficacy of GWP42003-P as an adjunctive antiepileptic treatment compared with placebo, with respect to the percentage change from baseline during the treatment period of the study in convulsive seizure frequency in children and young adults. Following the establishment of initial eligibility and baseline measurements, participants entered Part B and began a 28-day baseline observation period. Eligible participants were then randomized to receive either GWP42003-P or placebo on a 1:1 basis and titrated up to the target dose that was identified in Part A (up to 20 milligrams \[mg\] per kilogram \[kg\] per day), which was confirmed following completion of Part A by an independent Data Safety Monitoring Committee who reviewed unblinded safety and pharmacokinetic data from Part A. Participants received investigational medicinal product for 14 weeks, consisting of a titration period followed by a 12-week maintenance period. Efficacy and safety were monitored at various clinic visits and via telephone. After 14 weeks of treatment, all participants were offered the option of entering an open label extension (OLE) study. Entry was within seven days of the final treatment visit. Participants who did not immediately enter the OLE study commenced a down-titration taper period lasting up to 10 days. The taper period was interrupted if the participant wished to enter the open label extension study within the seven-day timeframe. For participants who opted not to enter the OLE study, a follow-up telephone call was made 28 days after the end of dosing and weekly safety telephone calls were made during the 28-day follow-up period.
Interventions
GWP42003-P was an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) dissolved in the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
DRUGPlacebo control
Placebo oral solution contained the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Sponsors
Jazz Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
2 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Participants were male or female aged between 2 and 18 years (inclusive). * Participants had a documented history of Dravet Syndrome that was not completely controlled by current antiepileptic drugs. * Participants took one or more antiepileptic drugs at a dose that had been stable for at least four weeks. * All medications or interventions for epilepsy (including ketogenic diet and vagus nerve stimulation) were stable for four weeks prior to screening and participants were willing to maintain a stable regimen throughout the study. Key
Exclusion criteria
* Participants had clinically significant unstable medical conditions other than epilepsy. * Participants had clinically relevant symptoms or a clinically significant illness in the four weeks prior to screening or randomization, other than epilepsy. * Participants were currently using or had in the past used recreational or medicinal cannabis or synthetic cannabinoid based medications (including Sativex®) within the three months prior to study entry and were unwilling to abstain for the duration for the study. * Participants had any known or suspected hypersensitivity to cannabinoids or any of the excipients of the investigational medicinal products. * Participants had been part of a previous clinical trial involving another investigational product in the previous six months. * There were plans for the participants to travel outside their country of residence during the study. * Participants previously randomized into this study. In particular, participants who participated in Part A of the study could not enter Part B.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period | Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET) | Convulsive seizures (atonic, clonic, tonic, or tonic-clonic) were recorded by the participant or caregiver using an interactive voice response system (IVRS) diary. Percentage change from baseline was calculated as: (\[frequency during the treatment period - frequency during baseline\]/frequency during baseline) \* 100. The frequency during each period was based on 28-day averages and calculated as: (number of seizures in the period/number of reported days in the IVRS period) \* 28. Baseline included all available data prior to Day 1 (28-day average). Negative percentages show an improvement from baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With A ≥25%, ≥75% Or 100% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period | Baseline to EOT (Day 99) or ET | Convulsive seizures (atonic, clonic, tonic, or tonic-clonic) were recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure. |
| Percentage Change From Baseline In Non-Convulsive Seizure Frequency During The Treatment Period | Baseline to EOT (Day 99) or ET | Non-convulsive seizures (myoclonic, partial, or absence) were recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure. Only participants with non-convulsive seizures during the baseline period were included. Negative percentages show an improvement from baseline. |
| Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Baseline to EOT (Day 99) or ET | Seizure duration was assessed qualitatively using the CGICSD. Caregivers were asked Since the patient started treatment, please assess the average duration of the patient's seizures (comparing their condition now to their condition before treatment); responses included decrease, no change, or increase in average duration. For each seizure type, only participants with at least 1 seizure for the corresponding seizure type, reported at any time during the study, were included. |
| Number Of Participants Using Rescue Medication | Baseline to EOT (Day 99) or ET | The use of rescue medication was recorded by the participant or caregiver using a paper diary. |
| Number Of Participants With Inpatient Hospitalizations Due To Epilepsy | Baseline to Safety Follow-up (Day 137) | Inpatient hospitalizations due to epilepsy were recorded by the participant or caregiver and through the serious adverse events (SAE) reporting process. |
| Number Of Participants With A ≥50% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period | Baseline to EOT (Day 99) or ET | Convulsive seizures (atonic, clonic, tonic, or tonic-clonic) were recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure. |
| Change From Baseline In Epworth Sleepiness Scale (ESS) Score | Baseline to Last Visit (Day 99) or ET | The ESS questionnaire was completed by the participant's caregiver. The change from baseline in the ESS score was analyzed using an ANCOVA model with baseline and age group (2 to 5 years, 6- to 2 years and 13 to 18 years) as covariates and treatment group as a fixed factor. The total score was the sum of the 8 item-scores and ranged from 0 to 24. A higher total score represents greater levels of daytime sleepiness. |
| Change From Baseline In Quality Of Life In Childhood Epilepsy (QOLCE) Score | Baseline to EOT (Day 99) or ET | The QOLCE questionnaire was completed by the parent or caregiver of participants aged 4 years and above. The change from baseline in the overall quality of life score was analyzed using an ANCOVA model with baseline and age group (2 to 5 years, 6 to 12 years and 13 to 18 years) as covariates and treatment group as a fixed factor. Zero represents the lowest or poorest category and 100 represents the highest level of functioning. The overall quality of life score was calculated by taking the mean of the subscale scores. |
| Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score | Baseline to Last Visit (Day 99) or ET | The Vineland-II scores (standard scores and adaptive levels for each adaptive behavior domain, the adaptive behavior composite, and the maladaptive behavior index score and level) were assessed by the participant's caregiver. Scores were analyzed using an ANCOVA model with baseline and age group (2 to 5 years, 6 to 12 years, and 13 to 18 years) as covariates and treatment group as a fixed factor. Higher scores represent greater levels of functioning except for the maladaptive behavior index, for which a negative change from baseline represents an improvement in condition. |
| Caregiver Global Impression Of Change (CGIC) | Baseline to Last Visit (Day 99) or ET | The CGIC was used to assess the participant's overall condition on a 7-point scale using the markers very much improved, much improved, slightly improved, no change, slightly worse, much worse, or very much worse (1 = very much improved; 7 = very much worse). On Day 1 (prior to starting IMP), the caregiver was asked to write a brief description of the participant's overall condition as a memory aid for the CGIC questionnaire at subsequent visits. |
| Change From Baseline In Sleep Disruption 0 To 10 Numerical Rating Scale (0 to 10 NRS) Score | Baseline to Last Visit (Day 99) or ET | The sleep disruption 0 to 10 NRS questionnaire was completed by the participant's caregiver. The caregiver was asked 'On a scale of '0 to 10', please indicate the number that best describes your child's sleep disruption in the last week.' The markers ranged from 0 = 'slept extremely well' to 10 = 'unable to sleep at all'. The change from baseline in the sleep disruption 0 to 10 numerical rating scale score was analyzed using an analysis of covariance (ANCOVA) model with baseline and age group (2 to 5 years, 6 to 12 years and 13 to 18 years) as covariates and treatment group as a fixed factor. A negative change from baseline represents an improvement in sleep. Last visit for endpoints assessed at clinic visits was defined as the last scheduled visit (not including the end of taper or safety follow-up visits) at which participant's last evaluation was performed. |
Countries
France, Poland, United Kingdom, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| GWP42003-P 20 mg/kg/Day Dose Participants received 20 mg/kg/day of GWP42003-P administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period. Participants received at least 1 dose of IMP; analyzed according to the actual treatment received (GWP42003-P). | 61 |
| Placebo Participants received placebo (0 mg/mL CBD), volume-matched to the 20 mg/kg/day dose level, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period. Participants received at least 1 dose of IMP; analyzed according to the actual treatment received (placebo). | 59 |
| Total | 120 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 8 | 1 |
| Overall Study | Lost to Follow-up | 0 | 1 |
| Overall Study | Withdrawal by Subject | 0 | 1 |
| Overall Study | Withdrawn by the investigator | 1 | 0 |
Baseline characteristics
| Characteristic | GWP42003-P 20 mg/kg/Day Dose | Placebo | Total |
|---|---|---|---|
| Age, Continuous | 9.736 Years STANDARD_DEVIATION 4.7309 | 9.779 Years STANDARD_DEVIATION 4.8505 | 9.757 Years STANDARD_DEVIATION 4.7699 |
| Sex: Female, Male Female | 26 Participants | 32 Participants | 58 Participants |
| Sex: Female, Male Male | 35 Participants | 27 Participants | 62 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 46 / 61 | 28 / 59 |
| serious Total, serious adverse events | 10 / 61 | 3 / 59 |
Outcome results
Primary
Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period
Convulsive seizures (atonic, clonic, tonic, or tonic-clonic) were recorded by the participant or caregiver using an interactive voice response system (IVRS) diary. Percentage change from baseline was calculated as: (\[frequency during the treatment period - frequency during baseline\]/frequency during baseline) \* 100. The frequency during each period was based on 28-day averages and calculated as: (number of seizures in the period/number of reported days in the IVRS period) \* 28. Baseline included all available data prior to Day 1 (28-day average). Negative percentages show an improvement from baseline.
Time frame: Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)
Population: ITT analysis set: included all participants in the Part B safety analysis set who had post-baseline efficacy data. Participants were analyzed according to the treatment group to which they were randomized. The ITT analysis set was the primary analysis set for all efficacy outcome measures.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| GWP42003-P 20 mg/kg/Day Dose | Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period | -38.94 percent change |
| Placebo | Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period | -13.29 percent change |
p-value: 0.012395% CI: [-41.06, -5.43]Wilcoxon rank-sum test
Secondary
Caregiver Global Impression Of Change (CGIC)
The CGIC was used to assess the participant's overall condition on a 7-point scale using the markers very much improved, much improved, slightly improved, no change, slightly worse, much worse, or very much worse (1 = very much improved; 7 = very much worse). On Day 1 (prior to starting IMP), the caregiver was asked to write a brief description of the participant's overall condition as a memory aid for the CGIC questionnaire at subsequent visits.
Time frame: Baseline to Last Visit (Day 99) or ET
Population: ITT analysis set: included all participants in the Part B safety analysis set who had post-baseline efficacy data. Participants were analyzed according to the treatment group to which they were randomized. The ITT analysis set was the primary analysis set for all efficacy outcome measures.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change (CGIC) | Slightly Improved | 18 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change (CGIC) | Slightly Worse | 3 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change (CGIC) | Much Improved | 10 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change (CGIC) | Much Worse | 4 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change (CGIC) | No Change | 15 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change (CGIC) | Very Much Worse | 1 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change (CGIC) | Very Much Improved | 9 Participants |
| Placebo | Caregiver Global Impression Of Change (CGIC) | Very Much Worse | 0 Participants |
| Placebo | Caregiver Global Impression Of Change (CGIC) | Very Much Improved | 4 Participants |
| Placebo | Caregiver Global Impression Of Change (CGIC) | Much Improved | 4 Participants |
| Placebo | Caregiver Global Impression Of Change (CGIC) | Slightly Improved | 12 Participants |
| Placebo | Caregiver Global Impression Of Change (CGIC) | No Change | 31 Participants |
| Placebo | Caregiver Global Impression Of Change (CGIC) | Slightly Worse | 6 Participants |
| Placebo | Caregiver Global Impression Of Change (CGIC) | Much Worse | 1 Participants |
Secondary
Caregiver Global Impression Of Change In Seizure Duration (CGICSD)
Seizure duration was assessed qualitatively using the CGICSD. Caregivers were asked Since the patient started treatment, please assess the average duration of the patient's seizures (comparing their condition now to their condition before treatment); responses included decrease, no change, or increase in average duration. For each seizure type, only participants with at least 1 seizure for the corresponding seizure type, reported at any time during the study, were included.
Time frame: Baseline to EOT (Day 99) or ET
Population: ITT analysis set: included all participants in the Part B safety analysis set who had post-baseline efficacy data. Participants were analyzed according to the treatment group to which they were randomized. The ITT analysis set was the primary analysis set for all efficacy outcome measures.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Tonic Seizures | No change in average duration | 8 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Tonic Seizures | Increase in average duration | 0 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Tonic-Clonic Seizures | Decrease in average duration | 17 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Tonic-Clonic Seizures | No change in average duration | 32 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Tonic-Clonic Seizures | Increase in average duration | 0 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Tonic Seizures | Decrease in average duration | 4 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Clonic Seizures | Decrease in average duration | 5 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Clonic Seizures | No change in average duration | 6 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Clonic Seizures | Increase in average duration | 0 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Atonic Seizures | Decrease in average duration | 2 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Atonic Seizures | No change in average duration | 1 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Atonic Seizures | Increase in average duration | 0 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Myoclonic Seizures | Decrease in average duration | 4 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Myoclonic Seizures | No change in average duration | 10 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Myoclonic Seizures | Increase in average duration | 0 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Countable Partial Seizures | Decrease in average duration | 5 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Countable Partial Seizures | No change in average duration | 7 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Countable Partial Seizures | Increase in average duration | 0 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Other Partial Seizures | Decrease in average duration | 0 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Other Partial Seizures | No change in average duration | 3 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Other Partial Seizures | Increase in average duration | 0 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Absence Seizures | Decrease in average duration | 4 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Absence Seizures | No change in average duration | 11 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Absence Seizures | Increase in average duration | 1 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Absence Seizures | No change in average duration | 12 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Tonic Seizures | No change in average duration | 12 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Myoclonic Seizures | Decrease in average duration | 3 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Other Partial Seizures | Decrease in average duration | 3 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Tonic-Clonic Seizures | Decrease in average duration | 8 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Myoclonic Seizures | No change in average duration | 12 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Tonic-Clonic Seizures | No change in average duration | 31 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Absence Seizures | Decrease in average duration | 6 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Tonic-Clonic Seizures | Increase in average duration | 2 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Myoclonic Seizures | Increase in average duration | 3 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Tonic Seizures | Decrease in average duration | 2 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Tonic Seizures | Increase in average duration | 1 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Other Partial Seizures | No change in average duration | 2 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Clonic Seizures | Decrease in average duration | 3 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Countable Partial Seizures | Decrease in average duration | 2 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Clonic Seizures | No change in average duration | 3 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Absence Seizures | Increase in average duration | 1 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Clonic Seizures | Increase in average duration | 1 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Countable Partial Seizures | No change in average duration | 9 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Atonic Seizures | Decrease in average duration | 2 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Other Partial Seizures | Increase in average duration | 0 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Atonic Seizures | No change in average duration | 3 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Countable Partial Seizures | Increase in average duration | 2 Participants |
| Placebo | Caregiver Global Impression Of Change In Seizure Duration (CGICSD) | Atonic Seizures | Increase in average duration | 2 Participants |
Secondary
Change From Baseline In Epworth Sleepiness Scale (ESS) Score
The ESS questionnaire was completed by the participant's caregiver. The change from baseline in the ESS score was analyzed using an ANCOVA model with baseline and age group (2 to 5 years, 6- to 2 years and 13 to 18 years) as covariates and treatment group as a fixed factor. The total score was the sum of the 8 item-scores and ranged from 0 to 24. A higher total score represents greater levels of daytime sleepiness.
Time frame: Baseline to Last Visit (Day 99) or ET
Population: ITT analysis set: included all participants in the Part B safety analysis set who had post-baseline efficacy data. Participants were analyzed according to the treatment group to which they were randomized. The ITT analysis set was the primary analysis set for all efficacy outcome measures.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| GWP42003-P 20 mg/kg/Day Dose | Change From Baseline In Epworth Sleepiness Scale (ESS) Score | 0.82 units on a scale |
| Placebo | Change From Baseline In Epworth Sleepiness Scale (ESS) Score | -0.69 units on a scale |
Secondary
Change From Baseline In Quality Of Life In Childhood Epilepsy (QOLCE) Score
The QOLCE questionnaire was completed by the parent or caregiver of participants aged 4 years and above. The change from baseline in the overall quality of life score was analyzed using an ANCOVA model with baseline and age group (2 to 5 years, 6 to 12 years and 13 to 18 years) as covariates and treatment group as a fixed factor. Zero represents the lowest or poorest category and 100 represents the highest level of functioning. The overall quality of life score was calculated by taking the mean of the subscale scores.
Time frame: Baseline to EOT (Day 99) or ET
Population: ITT analysis set: included all participants in the Part B safety analysis set who had post-baseline efficacy data. Participants were analyzed according to the treatment group to which they were randomized. The ITT analysis set was the primary analysis set for all efficacy outcome measures.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| GWP42003-P 20 mg/kg/Day Dose | Change From Baseline In Quality Of Life In Childhood Epilepsy (QOLCE) Score | 5.6 units on a scale |
| Placebo | Change From Baseline In Quality Of Life In Childhood Epilepsy (QOLCE) Score | 4.1 units on a scale |
Secondary
Change From Baseline In Sleep Disruption 0 To 10 Numerical Rating Scale (0 to 10 NRS) Score
The sleep disruption 0 to 10 NRS questionnaire was completed by the participant's caregiver. The caregiver was asked 'On a scale of '0 to 10', please indicate the number that best describes your child's sleep disruption in the last week.' The markers ranged from 0 = 'slept extremely well' to 10 = 'unable to sleep at all'. The change from baseline in the sleep disruption 0 to 10 numerical rating scale score was analyzed using an analysis of covariance (ANCOVA) model with baseline and age group (2 to 5 years, 6 to 12 years and 13 to 18 years) as covariates and treatment group as a fixed factor. A negative change from baseline represents an improvement in sleep. Last visit for endpoints assessed at clinic visits was defined as the last scheduled visit (not including the end of taper or safety follow-up visits) at which participant's last evaluation was performed.
Time frame: Baseline to Last Visit (Day 99) or ET
Population: ITT analysis set: included all participants in the Part B safety analysis set who had post-baseline efficacy data. Participants were analyzed according to the treatment group to which they were randomized. The ITT analysis set was the primary analysis set for all efficacy outcome measures.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| GWP42003-P 20 mg/kg/Day Dose | Change From Baseline In Sleep Disruption 0 To 10 Numerical Rating Scale (0 to 10 NRS) Score | -0.7 units on a scale |
| Placebo | Change From Baseline In Sleep Disruption 0 To 10 Numerical Rating Scale (0 to 10 NRS) Score | -0.3 units on a scale |
Secondary
Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score
The Vineland-II scores (standard scores and adaptive levels for each adaptive behavior domain, the adaptive behavior composite, and the maladaptive behavior index score and level) were assessed by the participant's caregiver. Scores were analyzed using an ANCOVA model with baseline and age group (2 to 5 years, 6 to 12 years, and 13 to 18 years) as covariates and treatment group as a fixed factor. Higher scores represent greater levels of functioning except for the maladaptive behavior index, for which a negative change from baseline represents an improvement in condition.
Time frame: Baseline to Last Visit (Day 99) or ET
Population: ITT analysis set: included all participants in the Part B safety analysis set who had post-baseline efficacy data. Participants were analyzed according to the treatment group to which they were randomized. The ITT analysis set was the primary analysis set for all efficacy outcome measures.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) |
|---|---|---|---|
| GWP42003-P 20 mg/kg/Day Dose | Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score | Communication Domain Standard Score | -0.8 units on a scale |
| GWP42003-P 20 mg/kg/Day Dose | Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score | Daily Living Skills Domain Standard Score | -0.8 units on a scale |
| GWP42003-P 20 mg/kg/Day Dose | Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score | Socialization Domain Standard Score | -0.6 units on a scale |
| GWP42003-P 20 mg/kg/Day Dose | Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score | Motor Skills Domain Standard Score | -2.5 units on a scale |
| GWP42003-P 20 mg/kg/Day Dose | Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score | Adaptive Behavior Composite Standard Score | -2.0 units on a scale |
| GWP42003-P 20 mg/kg/Day Dose | Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score | Maladaptive Behavior Index v-Scale Score | -0.3 units on a scale |
| Placebo | Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score | Adaptive Behavior Composite Standard Score | 0.6 units on a scale |
| Placebo | Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score | Communication Domain Standard Score | 3.0 units on a scale |
| Placebo | Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score | Motor Skills Domain Standard Score | 1.7 units on a scale |
| Placebo | Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score | Daily Living Skills Domain Standard Score | -0.8 units on a scale |
| Placebo | Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score | Maladaptive Behavior Index v-Scale Score | -0.4 units on a scale |
| Placebo | Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score | Socialization Domain Standard Score | -0.6 units on a scale |
Secondary
Number Of Participants Using Rescue Medication
The use of rescue medication was recorded by the participant or caregiver using a paper diary.
Time frame: Baseline to EOT (Day 99) or ET
Population: Safety Analysis Set: included all participants randomized to treatment who received at least 1 dose of IMP. Participants were analyzed according to the actual treatment they received.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GWP42003-P 20 mg/kg/Day Dose | Number Of Participants Using Rescue Medication | 36 Participants |
| Placebo | Number Of Participants Using Rescue Medication | 41 Participants |
Secondary
Number of Participants With A ≥25%, ≥75% Or 100% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period
Convulsive seizures (atonic, clonic, tonic, or tonic-clonic) were recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure.
Time frame: Baseline to EOT (Day 99) or ET
Population: ITT analysis set: included all participants in the Part B safety analysis set who had post-baseline efficacy data. Participants were analyzed according to the treatment group to which they were randomized. The ITT analysis set was the primary analysis set for all efficacy outcome measures.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GWP42003-P 20 mg/kg/Day Dose | Number of Participants With A ≥25%, ≥75% Or 100% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period | ≥25% Reduction | 38 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Number of Participants With A ≥25%, ≥75% Or 100% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period | ≥75% Reduction | 14 Participants |
| GWP42003-P 20 mg/kg/Day Dose | Number of Participants With A ≥25%, ≥75% Or 100% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period | 100% Reduction | 3 Participants |
| Placebo | Number of Participants With A ≥25%, ≥75% Or 100% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period | ≥25% Reduction | 26 Participants |
| Placebo | Number of Participants With A ≥25%, ≥75% Or 100% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period | ≥75% Reduction | 7 Participants |
| Placebo | Number of Participants With A ≥25%, ≥75% Or 100% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period | 100% Reduction | 0 Participants |
Secondary
Number Of Participants With A ≥50% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period
Convulsive seizures (atonic, clonic, tonic, or tonic-clonic) were recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure.
Time frame: Baseline to EOT (Day 99) or ET
Population: ITT analysis set: included all participants in the Part B safety analysis set who had post-baseline efficacy data. Participants were analyzed according to the treatment group to which they were randomized. The ITT analysis set was the primary analysis set for all efficacy outcome measures.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GWP42003-P 20 mg/kg/Day Dose | Number Of Participants With A ≥50% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period | 26 Participants |
| Placebo | Number Of Participants With A ≥50% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period | 16 Participants |
p-value: 0.078495% CI: [0.93, 4.3]Cochran-Mantel-Haenszel
Secondary
Number Of Participants With Inpatient Hospitalizations Due To Epilepsy
Inpatient hospitalizations due to epilepsy were recorded by the participant or caregiver and through the serious adverse events (SAE) reporting process.
Time frame: Baseline to Safety Follow-up (Day 137)
Population: ITT analysis set: included all participants in the Part B safety analysis set who had post-baseline efficacy data. Participants were analyzed according to the treatment group to which they were randomized. The ITT analysis set was the primary analysis set for all efficacy outcome measures.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| GWP42003-P 20 mg/kg/Day Dose | Number Of Participants With Inpatient Hospitalizations Due To Epilepsy | Caregiver/participant-reported | 5 participants |
| GWP42003-P 20 mg/kg/Day Dose | Number Of Participants With Inpatient Hospitalizations Due To Epilepsy | Investigator-reported (serious TEAE) | 2 participants |
| Placebo | Number Of Participants With Inpatient Hospitalizations Due To Epilepsy | Caregiver/participant-reported | 1 participants |
| Placebo | Number Of Participants With Inpatient Hospitalizations Due To Epilepsy | Investigator-reported (serious TEAE) | 1 participants |
Secondary
Percentage Change From Baseline In Non-Convulsive Seizure Frequency During The Treatment Period
Non-convulsive seizures (myoclonic, partial, or absence) were recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure. Only participants with non-convulsive seizures during the baseline period were included. Negative percentages show an improvement from baseline.
Time frame: Baseline to EOT (Day 99) or ET
Population: ITT analysis set: included all participants in the Part B safety analysis set who had post-baseline efficacy data. Participants were analyzed according to the treatment group to which they were randomized. The ITT analysis set was the primary analysis set for all efficacy outcome measures.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| GWP42003-P 20 mg/kg/Day Dose | Percentage Change From Baseline In Non-Convulsive Seizure Frequency During The Treatment Period | -40.16 percent change |
| Placebo | Percentage Change From Baseline In Non-Convulsive Seizure Frequency During The Treatment Period | -34.69 percent change |